Trending Market News
Moderna and Merck achieved a breakthrough with their mRNA cancer vaccine, marking the first successful therapeutic cancer vaccine in late-stage testing after over a century of failed attempts. In a trial of more than 1,000 melanoma patients, the personalized vaccine prevented tumors from recurring or spreading when combined with Merck's Keytruda. U.S. approval could come as soon as next year, offering Moderna a lifeline amid declining COVID vaccine demand and Merck a valuable asset ahead of Keytruda's patent expiration.
- Merck paid $200 million upfront in 2016 and $250 million in 2022 for the partnership, with Wall Street already estimating billions in potential sales for the approved vaccine
- The vaccine (intismeran autogene) targets up to 34 patient-specific cancer mutations using mRNA technology, paired with Keytruda to unleash immune system T-cells against tumors
- The companies are testing whether the approach works in cancers with fewer mutations, including lung, kidney, and pancreatic cancers, while refining the current melanoma vaccine
Cytokinetics presented late-stage trial data showing its heart drug aficamten significantly improved symptoms in patients with non-obstructive hypertrophic cardiomyopathy (nHCM), a genetic heart condition with no approved treatments. The company plans to file for expanded U.S. approval in Q4 2026, with analysts forecasting over $5 billion in peak sales for the drug across both obstructive and non-obstructive forms of the condition.
- 53% of patients on aficamten showed meaningful improvements in at least three of five key disease areas compared to just 13% on placebo in the 517-patient study
- Safety concerns emerged as 10% of patients experienced dangerous drops in heart pumping capacity and 12 heart failure events occurred during the study, attributed to rigid trial dosing protocols
- Cytokinetics is expected to hold the nHCM market alone for multiple years before Bristol Myers begins late-stage trials of rival drug Camzyos later this year
Chinese food delivery giant Meituan reported a return to profitability in Q2 2026, posting adjusted net profit of 2.16 billion yuan after a quarterly loss, as intense price competition in China's instant delivery market eased following regulatory pressure. Revenue reached 104.6 billion yuan, up 14.4% year-over-year and beating analyst expectations.
- Meituan swung to 2.16 billion yuan adjusted net profit from a 4.97 billion yuan loss in Q1, driven by subsiding price wars that regulators criticized as a 'race to the bottom'
- Competition intensified after Alibaba's Taobao and JD.com launched instant retail platforms in early 2025, pressuring Meituan's margins for over a year before easing in 2026
- China's market regulator fined seven e-commerce platforms including Meituan a combined 3.6 billion yuan in April over food delivery safety violations
Lucid is recalling 27,185 of its flagship Air luxury sedans in the U.S. due to a fire risk from an exterior lighting circuit that could overheat. The NHTSA announced the recall on Friday, advising owners to park vehicles outside and away from structures until the issue is resolved.
- The recall affects over 27,000 Lucid Air sedans due to an overheating exterior lighting circuit that increases fire risk
- NHTSA has instructed owners to park their vehicles outside and away from structures as a precautionary measure until repairs are completed
- Lucid has released an over-the-air software update to address the safety issue
Google has modified its spam policy in Europe to avoid potential antitrust fines under the EU's Digital Markets Act. The change addresses complaints from publishers that Google's site reputation abuse policy was demoting news media and publisher websites in search results when they included content from commercial partners. Starting August 30, manual demotion actions will not apply to users in the European Economic Area.
- The policy targets 'parasite SEO' where third-party pages abuse search rankings through host site signals, but EU regulators found it was harming legitimate publisher content
- Google will exempt the 27 EU nations plus Iceland, Norway, and Liechtenstein from manual site demotions, while maintaining the policy unchanged elsewhere
- The European Commission had opened a Digital Markets Act investigation, which can impose fines up to 10% of global annual turnover for violations
BioXcel Therapeutics, an AI-driven biopharmaceutical company, filed for Chapter 11 bankruptcy protection in Delaware on August 27. The company reported estimated liabilities of $100-500 million against assets of only $10-50 million, highlighting severe financial distress despite recent creditor support.
- BioXcel secured an amended credit agreement on Monday providing an additional $1.25 million in loans from creditors just days before the bankruptcy filing
- The company's liabilities ($100-500 million) far exceed its assets ($10-50 million), indicating a significant balance sheet deficit
- BioXcel focuses on neurological medications, with its experimental drug BXCL501 marketed as an acute treatment for agitation associated with Alzheimer's dementia
A consortium consisting of buyout firm Advent International and payment processor Stripe has abandoned its pursuit of acquiring PayPal, according to Bloomberg News citing sources familiar with the matter. Reuters could not immediately verify the report. The decision ends what would have been a major fintech consolidation deal.
- The buyout consortium included Advent International (private equity firm) and Stripe (payment processor)
- The target was PayPal, described as a 'fintech pioneer' in the digital payments space
- Reuters has not independently verified Bloomberg's report about the abandoned acquisition pursuit
Trump escalates rhetoric against Beijing as U.S.-China officials meet ahead of Xi's Washington visit
U.S. President Donald Trump escalated rhetoric against China by threatening sanctions on Chinese banks over Iran-related activities, even as officials from both countries met in Beijing to prepare for Chinese President Xi Jinping's planned state visit to Washington next month. Despite the tough rhetoric, both sides continue to focus on cooperation, signaling a balancing act between confrontation and diplomatic engagement.
- U.S. Treasury Secretary Scott Bessent warned Chinese banks could face sanctions if they participate in converting Iranian oil into money, though specific details remain limited and China's official response has been muted
- U.S. Ambassador David Perdue met with Chinese Foreign Minister Wang Yi and other officials in Beijing to prepare for Xi's upcoming Washington visit, with both sides confirming communication about the summit
- Analysts view the threats as largely performative, expecting the U.S.-China trade truce to remain intact as Beijing can comply with U.S. sanctions while maintaining its own legal framework for domestic operations
The U.S. Federal Trade Commission is investigating whether YouTube violated consumer protection laws by suspending user accounts and potentially misleading users about its content policies. The probe, which began last year, is in final stages and could result in a lawsuit against Alphabet's video-sharing platform, though some FTC career staff reportedly disagree with pursuing the case.
- The FTC is examining whether YouTube banned or demoted content in violation of its own user policies, potentially misleading users who signed up believing certain content was permitted
- The investigation is led by FTC Chairman Andrew Ferguson, who has signaled increased scrutiny of how online platforms enforce their speech policies
- Some career staff in the FTC's Bureau of Consumer Protection have privately expressed disagreement with filing the case, and investigations may end without enforcement action
BitGo has agreed to acquire NYDIG's institutional trading business to strengthen its position in crypto trading infrastructure. The deal will bring approximately 30 employees and 250 institutional client relationships to BitGo, expanding its services beyond custody into derivatives and capital markets. The acquisition comes amid growing mainstream adoption of cryptocurrencies under a crypto-friendly Trump administration.
- The acquisition adds about 30 NYDIG employees and 250 institutional client relationships to BitGo's operations
- BitGo will expand its service offerings to include derivatives, structured products, financing, and other capital markets services alongside its existing custody and wallet infrastructure
- BitGo went public earlier in 2025, raising approximately $213 million in its IPO, and is one of the largest crypto custody firms in the United States
The Trump administration is negotiating a deal with Venezuela to secure long-term U.S. access to a portion of Venezuela's oil reserves. The agreement would allow the U.S. government to designate specific Venezuelan oilfields for development by American companies, with the resulting oil supply guaranteed for the United States.
- The deal is being discussed at the highest levels of both governments and could be announced soon, with a 'lease' model under consideration as the legal framework
- Implementation would involve the U.S. locking in a group of Venezuelan oilfields, followed by auctions or tenders to allocate individual fields among American oil producers
- Neither the White House, U.S. Department of Energy, Venezuela's oil ministry, nor state oil company PDVSA provided immediate comment on the negotiations
The FDA approved Gilead's Bixlenvo, a once-daily HIV pill combining bictegravir and lenacapavir, designed to simplify treatment for patients whose virus is suppressed but who remain on complex multi-pill regimens. The drug targets an estimated 5% or more of HIV patients in the U.S. who cannot use existing single-tablet options due to drug resistance, side effects, or drug interactions. The approval is based on Phase 3 trials showing the pill maintained viral suppression at 48 weeks with minimal side effects.
- Bixlenvo is priced at $4,595 for a 30-day supply, in line with other daily single-tablet HIV treatments, with patient assistance programs available for uninsured and insured patients
- The drug combines bictegravir (from blockbuster Biktarvy) with lenacapavir, a first-in-class capsid inhibitor central to Gilead's long-term HIV strategy including daily pills and six-month injectables
- Phase 3 trials included patients with median age 60 taking 2-11 pills daily before switching, with most common side effects being headache, nausea and diarrhea in at least 2% of participants
The U.S. FDA has approved updated COVID-19 vaccines from Moderna, Novavax-Sanofi, and Pfizer-BioNTech for the 2026-27 season, targeting the dominant XFG variant. The approval follows an advisory panel's recommendation in May, where eight of nine experts voted in favor of targeting XFG. Four vaccine formulations were approved, including three mRNA-based shots and one protein-based vaccine.
- Four COVID vaccines approved: Moderna's mNEXSPIKE and Spikevax, Pfizer-BioNTech's Comirnaty (all mRNA-based), and Novavax-Sanofi's protein-based shot which requires longer manufacturing time
- The XFG variant target represents a shift from the 2025-26 season vaccines, which targeted the LP.8.1 subvariant of the JN.1 strain
- Current COVID strain data from the CDC is unavailable due to low sequencing submissions, though all manufacturers confirmed they can produce updated shots in time for the 2026-27 immunization season
Canada's ambassador to the U.S. stated that any trade deal must protect the Canadian auto assembly and parts industry, following the collapse of trade talks. President Trump imposed 50% tariffs on $20 billion in Canadian goods after negotiations failed, with Canada retaliating with $20 billion in tariffs set to take effect September 8.
- Trump's tariffs target Canadian wine, furniture, dairy, cement, clothing, fishing rods, and hockey equipment, bypassing protections under the existing three-nation trade deal with Mexico
- The breakdown centered on disagreements over tariff cuts for medium- and heavy-duty vehicles, with the U.S. Commerce Secretary claiming Canada raised the issue only in the final hours of talks
- Ambassador Wiseman emphasized Canada's 'resolve' and willingness to continue negotiations while preserving 'all options,' though no dates for resuming talks have been announced
Gap Inc. announced Michael Francis as the new CEO of Old Navy, effective November 2, replacing Haio Barbeito who held the position since 2022. The leadership change follows Old Navy's disappointing fiscal Q2 results, with comparable sales down 4% year-over-year, marking the brand's first negative same-store sales since Q2 2023. Old Navy contributes nearly 60% of Gap Inc.'s total revenue.
- Old Navy's Q2 net sales fell 4% to $2.1 billion, worse than the expected 2.4% decline, attributed to an 'unanticipated slowdown in traffic' and weak summer marketing that 'lacked a direct product message'
- Gap Inc. narrowed its full-year net sales growth outlook from 1-2% to 1-1.5% due to Old Navy's underperformance, though the company raised its adjusted EPS guidance
- Gap's namesake brand showed strong performance with comparable sales up 10% (beating 8.6% expectations), while Athleta struggled with a 12% decline in comparable sales
Ulta Beauty raised its annual sales and profit forecasts on August 27, citing strong beauty demand driven by marketing and product investments despite macroeconomic uncertainty. The cosmetics retailer increased its full-year sales growth outlook and comparable sales projections for fiscal 2026.
- Full-year sales growth forecast raised to 6.7%-7.2%, up from the prior range of 6%-7%
- Fiscal 2026 comparable sales now expected to grow 3.2%-3.7%, versus previous forecast of 2.5%-3.5%
- The upgrade reflects confidence that strategic investments in marketing and product assortment will sustain demand despite macroeconomic headwinds
Marvell Technology forecast third-quarter revenue of $3.15 billion, exceeding analyst estimates of $3.03 billion, driven by strong demand for custom chips and networking equipment used in AI data centers. The company's stock has nearly tripled in 2025 amid AI-driven optimism. Second-quarter sales rose 37% to $2.74 billion, also beating expectations.
- Marvell recently struck a deal with Google worth up to $120 billion in revenue through fiscal 2033, with Google taking a potential $12.2 billion stake in the company
- Growing demand stems from Big Tech companies developing custom in-house chips as cheaper alternatives to Nvidia's supply-constrained processors
- The shift from AI model training to deployment is boosting custom chip demand, as they offer better performance and efficiency than off-the-shelf processors
Anthropic plans to release its IPO prospectus after Labor Day, targeting a late September or early October listing, according to The Information. The AI startup is racing rival OpenAI to go public amid strong investor demand for artificial intelligence companies. The offering is expected to surpass the $86 billion raised by SpaceX in its June IPO.
- Anthropic is considering allowing existing shareholders to sell stock in the IPO, distinguishing it from recent tech listings like SpaceX and Cerebras which did not permit secondary sales
- The company has already raised at least $130 billion to support its compute infrastructure needs and is expected to exceed SpaceX's $86 billion June IPO
- Anthropic may require rank-and-file employees to sell shares in the offering, though the split between newly issued stock and secondary sales remains unclear
President Donald Trump is scheduled to meet with U.S. refiners and fuel retailers next week to address rising gasoline prices driven by the Iran conflict. The meeting aims to ease consumer pressure ahead of the November congressional midterm elections, as the administration seeks to demonstrate efforts to lower fuel costs.
- The meeting focuses on highlighting administration efforts to reduce gasoline prices amid heightened consumer concerns
- Rising gas prices are linked to ongoing conflict with Iran, creating economic pressure on voters before midterm elections
- The timing is politically significant as Trump's party seeks to mitigate potential electoral damage from higher fuel costs
A federal judge granted final approval to Bank of America's $72.5 million class-action settlement with women who accused the bank of facilitating sexual abuse by Jeffrey Epstein. The judge ruled the settlement provides substantial compensation despite objections from three accusers who argued it was overbroad in requiring them to release related claims without additional compensation.
- The settlement is part of broader litigation against Epstein's banks, following $290 million and $75 million settlements with JPMorgan Chase and Deutsche Bank respectively in 2023
- Lead plaintiff 'Jane Doe' alleged Epstein sexually abused her at least 100 times between 2011-2019, with money repeatedly wired through her Bank of America accounts
- Lawsuits accused banks of ignoring suspicious transactions to retain Epstein's business, even after his 2008 guilty plea to prostitution charges and sex offender registration